Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

(2011) Andrea L. Harzstark et al.   CANCER

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

(2011) P. Gulhati et al.   CANCER RESEARCH

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

(2011) T. C. Gangadhar et al.   CLINICAL CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer

(2009) P. Gulhati et al.   CLINICAL CANCER RESEARCH

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

(2009) Pippa Newell et al.   JOURNAL OF HEPATOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer

(2008) Lisa Simi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

(2008) Z. Wang et al.   CLINICAL CANCER RESEARCH

Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers

(2008) Zhi Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells

(2008) Konstantinos G. Lasithiotakis et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors

(2008) L. Dal Lago et al.   ONCOLOGIST

Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis

(2008) P. G. Rychahou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA